Amicus Therapeutics, Inc. (NASDAQ:FOLD) Given Average Recommendation of “Moderate Buy” by Analysts

Shares of Amicus Therapeutics, Inc. (NASDAQ:FOLD) have earned a consensus recommendation of “Moderate Buy” from the nine ratings firms that are presently covering the company, Marketbeat.com reports. Two investment analysts have rated the stock with a hold rating and seven have given a buy rating to the company. The average 12 month target price among analysts that have issued a report on the stock in the last year is $16.75.

FOLD has been the topic of a number of research reports. Cantor Fitzgerald reiterated an “overweight” rating and set a $21.00 price target on shares of Amicus Therapeutics in a research report on Wednesday, January 15th. JPMorgan Chase & Co. increased their target price on Amicus Therapeutics from $16.00 to $17.00 and gave the stock an “overweight” rating in a research report on Tuesday, November 12th. Needham & Company LLC reissued a “hold” rating on shares of Amicus Therapeutics in a report on Thursday, February 20th. Morgan Stanley restated an “equal weight” rating and set a $12.00 price target (down previously from $17.00) on shares of Amicus Therapeutics in a research report on Friday, December 13th. Finally, Guggenheim lifted their price objective on shares of Amicus Therapeutics from $13.00 to $15.00 and gave the company a “buy” rating in a research report on Thursday, November 7th.

Amicus Therapeutics Price Performance

Shares of NASDAQ:FOLD opened at $9.15 on Thursday. The company has a market cap of $2.81 billion, a PE ratio of -50.83, a P/E/G ratio of 1.51 and a beta of 0.61. Amicus Therapeutics has a fifty-two week low of $8.78 and a fifty-two week high of $13.49. The firm has a 50-day simple moving average of $9.48 and a 200 day simple moving average of $10.30. The company has a quick ratio of 2.42, a current ratio of 3.39 and a debt-to-equity ratio of 2.01.

Institutional Trading of Amicus Therapeutics

A number of hedge funds and other institutional investors have recently made changes to their positions in the stock. Vanguard Group Inc. increased its stake in shares of Amicus Therapeutics by 1.6% during the fourth quarter. Vanguard Group Inc. now owns 29,258,963 shares of the biopharmaceutical company’s stock valued at $275,619,000 after acquiring an additional 458,143 shares during the period. Wellington Management Group LLP boosted its stake in Amicus Therapeutics by 18.8% during the 4th quarter. Wellington Management Group LLP now owns 28,461,994 shares of the biopharmaceutical company’s stock valued at $268,112,000 after purchasing an additional 4,497,950 shares in the last quarter. Geode Capital Management LLC increased its position in shares of Amicus Therapeutics by 1.2% during the 3rd quarter. Geode Capital Management LLC now owns 6,599,871 shares of the biopharmaceutical company’s stock valued at $70,499,000 after purchasing an additional 80,926 shares during the period. Nuveen Asset Management LLC raised its stake in shares of Amicus Therapeutics by 4.4% in the 4th quarter. Nuveen Asset Management LLC now owns 3,807,420 shares of the biopharmaceutical company’s stock worth $35,866,000 after buying an additional 159,139 shares in the last quarter. Finally, Northern Trust Corp raised its stake in shares of Amicus Therapeutics by 5.9% in the 4th quarter. Northern Trust Corp now owns 3,371,639 shares of the biopharmaceutical company’s stock worth $31,761,000 after buying an additional 187,652 shares in the last quarter.

Amicus Therapeutics Company Profile

Amicus Therapeutics, Inc, a biotechnology company, focuses on discovering, developing, and delivering medicines for rare diseases. Its commercial product and product candidates include Galafold, an oral precision medicine for the treatment of adults with a confirmed diagnosis of Fabry disease and an amenable galactosidase alpha gene variant; and Pombiliti + Opfolda, for the treatment of late onset.